New drug combo shows promise in battle against advanced liver cancer
NCT ID NCT06530251
First seen Mar 19, 2026 · Last updated May 08, 2026 · Updated 5 times
Summary
This study tests a new drug, AK112, alone or with other treatments, for people with advanced liver cancer. The first part checks safety and the best dose, while the second part compares how well it works against standard therapies. About 280 participants will take part to see if this approach can control the disease better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)
RECRUITINGJinan, Shandong, China
Contact
Conditions
Explore the condition pages connected to this study.